

SUPPLEMENTARY DATA

**Antisense Inhibition of Protein Tyrosine Phosphatase 1B with IONIS-PTP-1B_{Rx}
Improves Insulin Sensitivity and Reduces Weight in Overweight Patients with Type 2
Diabetes**

Digenio A, et al.

Table of Contents

Table S1. Mean (SD) change in HbA1c at Week 27 categorized by baseline (BSLN) HbA1c levels.....	2
Figure S1. Study Design.....	3
Figure S2. Flow of Study Participants.....	4
Figure S3. Change in HbA1c levels over time by baseline HbA1c levels.....	5
Figure S4. A) Change from baseline of HbA1c versus change from baseline of body weight at Week 27 or early termination in IONIS-PTP-1B _{Rx} treated patients. B) Waterfall plot of change from baseline of HbA1c at week 36 compared to change from baseline in body weight at week 27.....	6
Primary Study Investigators.....	7

SUPPLEMENTARY DATA


Supplementary Table S1. Exploratory post-hoc analysis of mean (SD) change in HbA1c from baseline to Week 27 categorized by baseline (BSLN) HbA1c levels

Parameter	Placebo	IONIS-PTP-1B _{Rx} BSLN HbA1c ≤8%	IONIS-PTP-1B _{Rx} BSLN HbA1c >8 - ≤9%	IONIS-PTP-1B _{Rx} BSLN HbA1c >9%
HbA1c, %				
N	23	15	10	21
Baseline	8.4 (0.9)	7.6 (0.2)	8.6 (0.3)	9.7 (0.4)
N	23	14	10	21
Week 27, Change from Baseline	-0.1 (0.8)	-0.1 (0.6)	-0.6 (0.8)	-0.7 (0.9)
HbA1c, mmol/mol				
N	23	15	10	21
Baseline	68.2 (10.0)	59.8 (2.3)	70.0 (3.8)	82.4 (4.9)
N	23	14	10	21
Week 27, Change from Baseline	-0.7 (8.4)	-0.9 (7.1)	-6.2 (9.1)	-7.1 (9.8)

Baseline is defined as the last non-missing value prior to first dose.


SUPPLEMENTARY DATA

Supplementary Figure S1. Study Design



SUPPLEMENTARY DATA

Supplementary Figure S2. Flow of Study Participants



Abbreviations: AE, adverse event; PD, pharmacodynamics; PK, pharmacokinetics; SAE, serious adverse event

Analysis of PD was performed on the per-protocol population as defined in the methods section

*Reasons include withdrawn consent or sponsor decision


†Confirmed reduction of fasting plasma glucose >40 mg/dL from screening during 3-week pre-treatment period

‡Death from craniocerebral injury (not related)

§Patients were excluded from per-protocol population due to dose adjustment of OAD during treatment period (2 placebo, 4 IONIS-PTP-1B_{Rx})


SUPPLEMENTARY DATA

Supplementary Figure S3. Exploratory post-hoc analysis of change in HbA1c levels over time by baseline HbA1c levels. Baseline is defined as the last measure prior to first dose.



SUPPLEMENTARY DATA

Supplementary Figure S4. A) Change from baseline of HbA1c versus change from baseline of body weight at Week 27 or early termination in IONIS-PTP-1B_{Rx} treated patients. B) Waterfall plot of change from baseline of HbA1c at week 36 compared to change from baseline in body weight at week 27.



SUPPLEMENTARY DATA

Primary Study Investigators

Argentina

Georgina Daniela Sposetti, Mar del Plata, Buenos Aires

Mariana Lagrutta, Rosario, Santa Fe

Canada

Anil K. Gupta, MD, Toronto, Ontario

Arun Nayar, MBBS Saskatoon, Saskatchewan

Hasnain Khandwala, MBBS, FRCPC, Etobicoke, Ontario

Melanie Mason, MD, Vancouver, British Columbia

Robert Williams, MD, Kelowna, British Columbia

Ronnie Aronson, MD, FRCPC, FACE, Toronto, Ontario

South Africa

Ayesha Cassim Bassa, MBChB, Middelburg, Mpumalanga

Hester Johanna Kotze, MBChB, Centurion, Pretoria

Ismail Haroon Mitha, MBBCh, Benoni, Gauteng

Johannes Jurgens Lombaard, MBChB, Bloemfontein

Julian Trokis, Kraaifontein, Cape Town

Leon Frederik Fouche, MBChB, Thabazimbi, Limpopo

Lesley Jean Burgess, MBChB, MD, Parow, Cape Town

Mashra Gani, MBChB, Korsten, Port Elizabeth

Rajendran Moodley, MBChB, Tongaat

Tasneem Vally, MBChB, Meyerspark, Pretoria